Management of heart transplant recipients: Reference for primary care physicians

Postgraduate Medicine

Volumn 124, Issue 4, 2012, Pages 215-224

  Kansara, Pranav ^a   Kobashigawa, Jon A ^a  

^a CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Cardiac allograft vasculopathy; Drug interactions; Heart transplantation; Immunosuppression; Rejection

Indexed keywords

ALLOPURINOL; AMIODARONE; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CIMETIDINE; CLARITHROMYCIN; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; DILTIAZEM; DOXYCYCLINE; ERYTHROMYCIN; EVEROLIMUS; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; METHYLPREDNISOLONE; METHYLPREDNISOLONE SODIUM SUCCINATE; METOCLOPRAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICARDIPINE; NIFEDIPINE; OMEPRAZOLE; PLACEBO; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; UNINDEXED DRUG; VERAPAMIL; IMMUNOSUPPRESSIVE AGENT;

ABDOMINAL PAIN; ACNE; ACUTE KIDNEY FAILURE; ANEMIA; ANXIETY; ARTICLE; AVASCULAR NECROSIS; CAPILLARY RESISTANCE; CATARACT; COLITIS; CONTINUOUS INFUSION; CUSHINGOID SYNDROME; DIABETES MELLITUS; DIARRHEA; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DYSLIPIDEMIA; EMOTIONAL DISORDER; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GENERAL PRACTITIONER; GINGIVA HYPERPLASIA; GRAFT RECIPIENT; GRAFT REJECTION; GROWTH RETARDATION; HEART FAILURE; HEART TRANSPLANTATION; HIRSUTISM; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERTRICHOSIS; HYPERURICEMIA; HYPOMAGNESEMIA; IMMUNOSUPPRESSIVE TREATMENT; INSOMNIA; INTERSTITIAL LUNG DISEASE; KIDNEY DISEASE; KIDNEY FAILURE; LEUKOPENIA; LIVER DYSFUNCTION; MALIGNANT NEOPLASTIC DISEASE; MANAGED CARE; MYOPATHY; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OBESITY; OSTEOPOROSIS; PARESTHESIA; PEPTIC ULCER; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; RHINORRHEA; SEIZURE; SIDE EFFECT; SODIUM RETENTION; SURGICAL TECHNIQUE; SURVIVAL; THROMBOCYTOPENIA; TREATMENT INDICATION; TREMOR; VOMITING; WORK EXPERIENCE; ADULT; DISEASE MANAGEMENT; GENERAL PRACTICE; METHODOLOGY; REVIEW; TRANSPLANTATION;

ADULT; DISEASE MANAGEMENT; FAMILY PRACTICE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; POSTOPERATIVE COMPLICATIONS; TRANSPLANTATION;

EID: 84871689301     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2012.07.2563     Document Type: Article

References (38)

1. Stehlik J, Edwards LB, Kucheryavaya AY, et al. The registry of the International Society for Heart and Lung Transplantation: twenty-eighth adult heart transplant report-2011. J Heart Lung Transplant. 2011;30(10):1078-1094.
2. Kobashigawa JA. Postoperative management following heart transplantation. Transplant Proc. 1999;31(5):2038-2046.
3. Stark RP, McGinn AL, Wilson RF. Chest pain in cardiac transplant recipients. Evidence of sensory reinnervation after cardiac transplantation. N Engl J Med. 1991;324(25):1791-1794.
4. Kobashigawa JA, Leaf DA, Lee N, et al. A controlled trial of exercise rehabilitation after heart transplantation. N Engl J Med. 1999;340(4):272-277.
5. Kobashigawa JA, Miller LW, Russell SD, et al; Study Investigators. Tacrolimus with mycophenolate mofetil (MMF) or sirolimus vs. cyclosporin with MMF in cardiac transplant patients: 1-year report. Am J Transplant. 2006;6(6):1377-1386.
6. Kobashigawa JA, Patel J, Furukawa H, et al. Five-year results of a randomized, single-center study of tacrolimus vs microemulsion cyclosporin in heart transplant patients. J Heart Lung Transplant. 2006; 25(4):434-439.
7. Kobashigawa J, Miller L, Renlund D, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation. 1998;66(4):507-515.
8. Mancini D, Pinney S, Burkhoff D, et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation. 2003;108(1):48-53.
9. Eisen HJ, Tuzcu EM, Dorent R, et al; RAD B253 Study Group. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med. 2003;349(9):847-858.
10. Constanzo MR, Dipchand A, Starling R, et al; International Society of Heart and Lung Transplantation Guidelines. The International Society of Heart and Lung Transplantation guidelines for the care of heart transplant recipients. J Heart Lung Transplant. 2010;29(8):914-956.
11. O'Connell JB, Bourge RC, Costanzo-Nordin MR, et al. Cardiac transplantation: recipients selection, donor procurement, and medical follow-up. A statement for health professionals from the Committee on Cardiac Transplantation of the Council on Clinical Cardiology, American Heart Association. Circulation. 1992;86(3):1061-1079.
12. Zuckermann AO, Aliabidi AZ. Calcineurin-inhibitor minimization protocols in heart transplantation. Transpl Int. 2009;22(1):78-89.
13. Kobashigawa JA, Renlund DG, Gerosa G, et al; ERL2401 Heart Study Investigators. Similar efficacy and safety of enteric-coated mycophenolate sodium (EC-MPS, myfortic) compared with mycophenolate mofetil (MMF) in de novo heart transplant recipients: results of a 12-month, single-blind, randomized, parallel-group, multicenter study. J Heart Lung Transplant. 2006;25(8):935-941.
14. Kobashigawa JA, Stevenson LW, Brownfleld ED, et al. Initial success of steroid weaning late after heart transplantation. J Heart Lung Transplant. 1992;11(2 pt 2):428-430.
15. Kobashigawa JA, Stevenson LW, Brownfleld ED, et al. Corticosteroid weaning late after heart transplantation: relation to HLA-DR mismatching and long term metabolic benefits. J Heart Lung Transplant. 1995;14(5):963-967.
16. Patel JK, Kobashigawa JA. Everolimus for cardiac allograft v asculopathy-every patient, at any time? Transplantation. 2011;92(2):127-128.
17. Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant. 2005;24(11):1710-1720.
18. Kobashigawa J, Crespo-Leiro MG, Ensminger SM, et al; Consensus Conference Participants. Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transplant. 2011;30(3):252-269.
19. Kobashigawa JA, Stevenson LW, Moriguchi JD, et al. Is intravenous glucocorticoid therapy better than an oral regimen for asymptomatic cardiac rejection? A randomized trial. J Am Coll Cardiol. 1993;21(5):1142-1114.
20. Wu GW, Kobashigawa JA, Fishbein MC, et al. Asymptomatic antibody-mediated rejection after heart transplantation predicts poor outcomes. J Heart Lung Transplant. 2009;28(5):417-422.
21. Kosek JC, Hurley EJ, Lower RR. Histopathology of orthotopic canine cardiac homografts. Lab Invest. 1968;19(1):97-112.
22. Kosek JC, Hurley EJ, Sewell DH, Lower RR. Histopathology of orthotopic canine cardiac homografts and its clinical correlation. Transplant Proc. 1969;1(1):311-315.
23. Thomson JG. Production of severe atheroma in a transplanted human heart. Lancet. 1969;2(7630):1088-1092.
24. Bieber CP, Stinson EB, Shumway NE, Payne R, Kosek J. Cardiac transplantation in man. VII. Cardiac allograft pathology. Circulation. 1970;41(5):753-772.
25. Billingham ME. Histopathology of graft coronary disease. J Heart Lung Transplant. 1992;11(3 pt 2):S38-S44.
26. Day JD, Rayburn BK, Gaudin PB, et al. Cardiac allograft vasculopathy: the central pathogenetic role of ischemia-induced endothelial cell injury. J Heart Lung Transplant. 1995;14(6 pt 2):S142-S149.
27. Johnson MR. Transplant coronary disease: nonimmunologic risk factors. J Heart Lung Transplant. 1992;11(3 pt 2):S124-S132.
28. Winters G, Kendall TJ, Radio SJ, et al. Posttransplant obesity and hyperlipidemia: major predictors of severity of coronary arteriopathy in failed human heart allografts. J Heart Lung Transplant. 1990;9(4): 364-371.
29. Gibbons GH. The pathogenesis of graft vascular disease: implications of vascular remodeling. J Heart Lung Transplant. 1995;14(6 pt 2): S149-S158.
30. Gao SZ, Alderman EL, Schroeder JS, Silverman JF, Hunt SA. Accelerated coronary vascular disease in the heart transplant patient: coronary arteriographic findings. J Am Coll Cardiol. 1988;12(2):334-340.
31. Mehra MR, Crespo-Leiro MG, Dipchand A, et al. International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy-2010. J Heart Lung Transplant. 2010;29(7):717-727.
32. Kobashigawa JA, Tobis JM, Starling RC, et al. Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years. J Am Coll Cardiol. 2005;45(9):1532-1537.
33. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 1995; 333(10):621-627.
34. Cutts JL, Scallen TJ, Watson J, Bankhurst AD. Role of mevalonic acid in the regulation of natural killer cell cytotoxicity. J Cell Physiol. 1989;139(3);550-557.
35. Fang JC, Kinlay S, Beltrame J, et al. Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: a randomised trial. Lancet. 2002;359(9312):1108-1113.
36. Miller LW, Schlant RC, Kobashigawa J, Kubo S, Renlund DG. 24th Bethesda Conference: Cardiac Transplantation. Task Force 5: Complications. J Am Coll Cardiol. 1993;22(1):41-54.
37. Armitage JM, Kormos RL, Stuart RS, et al. Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression. J Heart Lung Transplant. 1991;10(6):877-887.
38. Kobashigawa JA. Pathophysiology of the transplanted heart and its influence on exercise tolerance. In: Balady GL, Pina IL, eds. Exercise and Heart Failure. Armonk, NY: Futura Publishing Company, Inc.; 1997.